Press Releases

Press Releases

Jun 19, 2012
PISCATAWAY, NJ -- (Marketwire) -- 06/19/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced the presentation of results from a Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors.
Jun 4, 2012
PISCATAWAY, NJ -- (MARKETWIRE) -- 06/04/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from the final analysis of a Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast cancer.
May 7, 2012
PISCATAWAY, NJ and ZHEJIANG, CHINA -- (Marketwire) -- 05/07/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) and Zhejiang Hisun Pharmaceuticals Co.
May 2, 2012
PISCATAWAY, NJ -- (Marketwire) -- 05/02/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the first quarter of 2012.
Mar 12, 2012
PISCATAWAY, NJ -- (MARKET WIRE) -- 03/12/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth-quarter and full-year 2011.
Dec 8, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 12/08/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from a Phase II, open-label study in which PEG-SN38 (EZN-2208) demonstrated notable activity in patients with previously treated metastatic breast cancer.
Nov 12, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/12/11 -- Enzon Pharmaceuticals, Inc.
Nov 3, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/03/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2011.
Oct 17, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 10/17/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that Ana I.
Sep 22, 2011
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it is implementing a plan to reduce its workforce and operating costs to more closely align its resources with the Company's research and development activities.